Imaging and Biomarkers of Hypoxia in Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- PET Scan
- Conditions
- Neoplasms
- Sponsor
- Stanford University
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- 18F-EF5 uptake (tumor: blood ratio) before and after carbogen breathing for a subset of subjects.
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the tumor with oxygenated blood. It is currently understood that hypoxic tumors are more aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to measure tumor hypoxia.
Detailed Description
To establish PET imaging with the tracer EF5 as an accurate and reliable method for measuring the oxygen content of a tumor and to establish the measurement of secreted markers in blood as an accurate and reliable method for measuring the oxygen content of a tumor.
Investigators
Billy W. Loo Jr.
Associate Professor of Radiation Oncology
Stanford University
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Carbogen arm
Intervention: PET Scan
Carbogen arm
Intervention: EF5
Carbogen arm
Intervention: Carbogen
DCA arm
Intervention: PET Scan
DCA arm
Intervention: EF5
DCA arm
Intervention: Dichloroacetate
Outcomes
Primary Outcomes
18F-EF5 uptake (tumor: blood ratio) before and after carbogen breathing for a subset of subjects.
Time Frame: 1-5 days
18F-EF5 uptake (tumor: blood ratio) before and after administration of DCA for a subset of subjects.
Time Frame: 1-5 days
Secondary Outcomes
- Levels of secreted hypoxia markers in plasma.(1-5 days)
- Hypoxia gene and protein expression scores in patients undergoing biopsy or surgical resection.(1-5 days)